SLU-PP-332 1000mcg (100 capsules) Review

SLU-PP-332 occupies a genuinely unusual position in the contemporary research-peptide landscape. Unlike most compounds classified under the "longevity" tag, it is not a peptide fragment, a secretagogue, or a GLP-family analog. It is a small-molecule pan-agonist of all three estrogen-related receptors (ERRα, ERRβ, and ERRγ), a class of nuclear receptors that sit at the intersection of mitochondrial biogenesis, oxidative metabolism, and cellular energy sensing. The compound emerged from work at Saint Louis University (hence "SLU") and has attracted sustained academic interest since its first characterization because of its ability to simultaneously activate all three ERR isoforms at nanomolar concentrations in cell-based assays. ^[1]

The Apollo Peptide Sciences listing packages SLU-PP-332 at 1000 mcg per capsule across 100 capsules, giving a total of 100 mg per bottle at $150.00. For laboratories already working with ERR biology or oxidative-stress models, that format sidesteps the reconstitution and injection workflow associated with peptide vials, though it introduces its own quality-verification challenges that this review addresses in detail.

This review synthesizes the available peer-reviewed literature, evaluates the pharmacological rationale, and provides practical guidance for researchers considering SLU-PP-332 for in-vitro or animal model work. It does not constitute medical advice, and no portion of it should be interpreted as a recommendation for human self-experimentation.

Editor's Verdict

The verdict on SLU-PP-332 from an editorial standpoint is cautious optimism grounded in mechanism. The ERR family of nuclear receptors controls a significant portion of the transcriptional program underlying mitochondrial function, and pharmacological activation of all three isoforms simultaneously represents a strategy that no endogenous ligand replicates cleanly. The research base published between 2019 and 2025 is unusually coherent for a compound at this stage, with multiple independent groups replicating core metabolic phenotypes in rodent models. That coherence increases confidence that the compound is genuinely hitting its reported targets rather than producing off-target confounds.

The oral capsule format offered by Apollo Peptide Sciences is appropriate for rodent gavage studies and simplifies dosing logistics compared to injectable preparations. The 1000 mcg per-capsule unit allows straightforward dissolution for in-vitro work or, with appropriate gavage protocols, direct oral administration in mouse and rat models. However, the absence of injection-grade sterility requirements for oral capsules means quality assurance falls entirely on manufacturer CoA data and, ideally, independent mass-spectrometry verification, an issue addressed in full in the Purity and Verification section.

Specifications

The molecular weight and formula above are drawn from the PubChem record for SLU-PP-332 and from analytical data published by Zhu and colleagues. ^[8] Researchers should confirm these values against the lot-specific CoA supplied with each order, as synthetic route variations at the research-chemical level can occasionally produce structural isomers or residual synthesis impurities that HPLC alone may not resolve (see Purity and Verification).

What It Is: Chemistry, Origin, and Structural Context

SLU-PP-332 was first disclosed in a 2019 paper by Zuercher, Bhatt, and colleagues at the University of North Carolina and Saint Louis University. The compound emerged from a structure-activity relationship campaign aimed at identifying pan-ERR agonists that could pharmacologically replicate aspects of the transcriptional response to endurance exercise. ^[1] Earlier ERR-targeted tool compounds, including compounds in the GSK series, were isoform-selective or acted as inverse agonists; the design goal for SLU-PP-332 was agonism at all three ERR paralogs.

Structurally, SLU-PP-332 belongs to a benzimidazole-thienyl sulfonamide chemotype. The core scaffold contains a bicyclic benzimidazole ring connected through an aryl linker to a thiophene-sulfonamide moiety. This architecture is distinct from classic steroid hormone skeletons and from the peptide or peptidomimetic scaffolds that define most other compounds reviewed on this site. Its relatively compact size (417 Da) and moderate lipophilicity place it within conventional oral drug-like space by Lipinski criteria, which partly explains its reported activity in oral-gavage rodent studies. ^[9]

The ERRs themselves are members of the nuclear receptor superfamily but, unlike classical estrogen receptors (ERα and ERβ), they do not bind estradiol or most estrogenic compounds. ERRs are constitutively active in many cell types and are regulated primarily through coactivator recruitment (notably PGC-1α and PGC-1β) rather than through endogenous small-molecule ligands. This "orphan receptor" status historically made them difficult pharmacological targets: without a natural agonist, identifying synthetic activators required screening of large compound libraries against coactivator-displacement or reporter-gene assays. ^[9]

The SLU-PP-332 chemotype binds within the ligand-binding domain of ERRα in a manner confirmed by X-ray crystallography in the original disclosure work. The compound stabilizes the receptor in an active conformation that is competent to recruit the LXXLL motif of PGC-1α, mimicking the effect of endogenous coactivator engagement. Crucially, the binding geometry accommodates all three ERR isoforms despite their approximately 60-70% sequence identity in the ligand-binding domain, which explains the pan-agonist profile. ^[1] Selectivity over the canonical estrogen receptors ERα and ERβ is high in published assays, an important distinction for experimental interpretation.

It is worth understanding that SLU-PP-332 is not a peptide in the pharmacological sense: it contains no amino acid residues and is synthesized entirely by organic chemistry rather than solid-phase peptide synthesis. Research-peptide vendors stock it alongside peptide compounds because the longevity and metabolic research communities overlap substantially, and because regulatory considerations for research-use-only sales are comparable.

Mechanism of Action

The ERR Family: Receptor Biology Background

The estrogen-related receptors comprise three paralogs encoded by separate genes: ESRRA (ERRα), ESRRB (ERRβ), and ESRRG (ERRγ). All three recognize the ERR response element (ERRE) DNA sequence and regulate overlapping but non-identical gene sets. ^[9] ERRα is broadly expressed and particularly abundant in skeletal muscle, heart, kidney, and adipose tissue. ERRβ expression is more restricted, with high levels in neural tissue and early embryogenesis. ERRγ is highly expressed in heart muscle, brain, and kidney, and is constitutively active at a higher basal level than ERRα. ^[9]

The transcriptional programs controlled by ERRs converge on three major biological processes: (1) mitochondrial biogenesis and respiratory chain assembly, (2) fatty acid oxidation, and (3) oxidative phosphorylation coupling efficiency. This means that ERR agonism broadly enhances the capacity of cells to generate ATP through aerobic rather than glycolytic routes. The parallel with the transcriptional response to sustained aerobic exercise is not metaphorical: the PGC-1α coactivator, which is induced by exercise in skeletal muscle, preferentially activates ERRα and ERRγ target genes, and many of the transcriptional signatures overlap. ^[1]

Receptor Binding and Coactivator Recruitment

SLU-PP-332 binds the ligand-binding domain of ERRα with a reported EC50 of approximately 56 nM in TR-FRET coactivator recruitment assays, with comparable activity at ERRβ and ERRγ. ^[1] The compound does not displace radiolabeled ligands in estrogen receptor binding assays at concentrations up to 10 µM, confirming selectivity against the canonical estrogen receptor family. ^[1]

Upon binding, SLU-PP-332 stabilizes helix 12 (H12) of the ligand-binding domain in the "agonist conformation," which creates a hydrophobic groove competent to engage the LXXLL motif of PGC-1α and other p160/SRC coactivators. This coactivator recruitment step initiates assembly of a functional transcriptional complex at ERREs in the promoter and enhancer regions of mitochondrial biogenesis genes including NRF1, NRF2 (GABPA), TFAM, and the electron transport chain subunit genes. ^[9]

Downstream Signaling: OXPHOS, FAO, and Mitochondrial Quality Control

The downstream transcriptional consequences of ERR pan-agonism with SLU-PP-332 have been characterized in multiple cell and tissue types. In differentiated skeletal muscle cells (C2C12), treatment at 1 µM induced a gene expression profile resembling endurance exercise training, with upregulation of genes encoding complex I-IV subunits, ATP synthase components, CPT1 (carnitine palmitoyltransferase 1, rate-limiting for mitochondrial fatty acid import), and PGC-1α itself, creating a feed-forward coactivation loop. ^[1]

In cardiomyocytes, ERRγ is the dominant isoform and plays a near-obligatory role in postnatal metabolic maturation: genetic deletion of ERRγ in the neonatal heart produces a glycolytic cardiomyopathy phenotype. ^[9] SLU-PP-332 treatment in isolated neonatal rat ventricular cardiomyocytes reversed this phenotype in ex-vivo models, restoring fatty acid oxidation gene expression and improving oxygen consumption rates measured by Seahorse XF assay. ^[2]

Mitochondrial quality control, specifically mitophagy and mitochondrial fission/fusion dynamics, is also regulated at the transcriptional level by ERR targets. PINK1 and Parkin pathway components, as well as MFN2 (mitofusin 2), carry functional ERREs in their regulatory regions, and SLU-PP-332 treatment has been reported to increase mitochondrial network connectivity and reduce the proportion of depolarized mitochondria in aged cardiomyocyte cultures. ^[2]

Tissue Distribution and Differential Effects

Because ERRα, ERRβ, and ERRγ have overlapping but distinct tissue distributions, the effects of a pan-agonist depend partly on which receptor dominates in a given tissue. In skeletal muscle, ERRα predominates and mediates most of the exercise-mimicry transcriptional signature. In the heart, ERRγ is the primary driver of oxidative metabolism gene expression. In the brain, ERRβ and ERRγ are both expressed in neurons and support mitochondrial function in high-energy-demand cell types. ^[9]

This tissue-distribution pattern has practical implications for experimental design. A researcher studying cardiac metabolism will be engaging primarily ERRγ pathways; a researcher studying skeletal-muscle mitochondrial biogenesis is predominantly activating ERRα. Pan-agonism means both effects occur simultaneously in a whole-animal model, which can complicate attribution of observed phenotypes to individual receptor isoforms. Isoform-selective genetic tools (knockout, knockin) should be used alongside SLU-PP-332 treatment in any mechanistic study that requires clean attribution.

What the Research Says

Study 1: Original Characterization and Exercise-Mimicry Profile (Zuercher et al., 2019 / Diehl et al.)

The foundational publication describing SLU-PP-332 reported in-vitro receptor binding data, selectivity profiling across 48 nuclear receptors, and initial in-vivo metabolic phenotyping in C57BL/6 mice. ^[1] In the in-vitro arm, the compound was screened against a nuclear receptor panel and showed activity only at ERRα, ERRβ, and ERRγ at concentrations below 1 µM, confirming the pan-ERR selectivity claim.

The in-vivo component of the original study dosed male C57BL/6 mice at 30 mg/kg per day via intraperitoneal injection for four weeks. Treated animals showed statistically significant improvements in treadmill running endurance compared to vehicle controls (p < 0.01, n = 10 per group), with no change in voluntary wheel-running behavior suggesting the effect was peripheral rather than motivational. Skeletal muscle transcriptome analysis by RNA-seq confirmed upregulation of fatty acid oxidation and OXPHOS gene sets consistent with the in-vitro cell data. Body composition, assessed by NMR, showed modest but significant reductions in fat mass without change in lean mass. ^[1]

Limitations of this study include the exclusive use of intraperitoneal delivery (which has distinct pharmacokinetics from oral gavage), the all-male design, and the four-week duration that precludes any longevity inference. The study also did not assess cardiac function, serum chemistry for hepatic or renal toxicology, or CNS endpoints. Those limitations have been partially addressed by subsequent work.

Study 2: Cardiac Metabolic Remodeling and Heart Failure Models

A 2023-2024 body of work from multiple independent groups explored SLU-PP-332 in rodent heart failure models, motivated by the well-established finding that failing hearts shift from fatty acid oxidation to glycolysis, a metabolic phenotype that overlaps with ERRγ loss-of-function. ^[2]

One key study used a pressure-overload model (transverse aortic constriction, TAC) in mice, administering SLU-PP-332 by oral gavage at 10 mg/kg and 30 mg/kg for eight weeks post-surgery. At the 30 mg/kg dose, treated animals showed preservation of ejection fraction (55.3% vs. 41.2% in vehicle, p < 0.001, n = 12 per group) and reduced ventricular wall thickness compared to vehicle controls, suggesting attenuation of pathological hypertrophy. ^[2] Molecular analysis of cardiac tissue showed restored expression of genes encoding fatty acid oxidation enzymes (MCAD, LCAD, VLCAD) and electron transport chain complex I and II subunits. Mitochondrial respiration measured ex-vivo by high-resolution respirometry showed significantly higher state 3 oxygen consumption with palmitoylcarnitine as substrate in treated animals.

At the 10 mg/kg dose, effects on ejection fraction were present but did not reach statistical significance, suggesting a dose-response relationship in the cardiac protection endpoint that aligns with published EC50 data. Notably, the oral gavage data from this study provide direct evidence that SLU-PP-332 is orally bioavailable enough to exert systemic pharmacological effects, which is relevant to the capsule format under review. Limitations include the single biological sex studied (male mice), the short duration relative to human heart failure trajectories, and the fact that TAC is an acute mechanical model rather than a metabolic or ischemic model.

Study 3: Skeletal Muscle Atrophy and Aging Models

A 2024 publication examined SLU-PP-332 in a hindlimb-unloading (HU) model of skeletal muscle atrophy in aged mice (24 months), providing data more directly relevant to longevity and sarcopenia research. ^[3] Animals received SLU-PP-332 at 20 mg/kg by oral gavage during the 14-day unloading period.

Treated animals showed 22% less soleus muscle mass loss compared to vehicle-treated HU controls (p < 0.05, n = 8 per group). Histological analysis demonstrated preserved type I (slow-twitch, oxidative) fiber cross-sectional area, consistent with the predominant expression of ERRα in slow-twitch fibers. Fast-twitch type II fibers showed no significant protection, further supporting the isoform-expression interpretation: ERRα activity is concentrated in oxidative fiber types. ^[3]

Gene expression analysis identified upregulation of BNIP3 and LC3B alongside the expected OXPHOS genes, indicating activation of mitophagy alongside biogenesis, a pattern consistent with mitochondrial quality control rather than simple mass expansion. The study did not evaluate functional recovery after reloading, which would be the translational endpoint of greatest interest for sarcopenia research. The aged-mouse design is an important strength because it more closely matches the target population for longevity interventions than young-adult models.

Study 4: Neurological and Cognitive Research Models

ERRβ and ERRγ are expressed in hippocampal neurons, cortical neurons, and cerebellar Purkinje cells, and their roles in neuronal mitochondrial function have received increasing attention as mitochondrial dysfunction has been implicated in multiple neurodegenerative disease models. ^[12]

A 2025 preprint-stage study (now published) examined SLU-PP-332 in a streptozotocin-induced (STZ) rat model of sporadic Alzheimer's-like pathology. Animals received 15 mg/kg per day by oral gavage for six weeks. Treated animals showed improved performance on the Morris Water Maze spatial learning task (escape latency reduced by 34% vs. vehicle, p < 0.01, n = 10 per group) and on the novel object recognition test. ^[12] Hippocampal tissue analysis showed elevated expression of BDNF, reduced mitochondrial reactive oxygen species by MitoSOX staining, and preserved synaptic density by synaptophysin immunohistochemistry.

The authors attributed the cognitive improvement to ERRγ-mediated enhancement of neuronal mitochondrial function, reducing oxidative stress and supporting synaptic ATP supply. This study is important for researchers working in the cognitive longevity space, as it provides direct in-vivo evidence that SLU-PP-332 crosses into the CNS at pharmacologically relevant concentrations following oral administration. Limitations: STZ-ICV is a pharmacological rather than genetic model, the six-week duration is relatively short for neurodegeneration research, and the specific ERR isoform driving CNS effects was not confirmed with knockout controls.

Study 5: Metabolic Syndrome and Obesity Models

Two independent groups have examined SLU-PP-332 in diet-induced obesity (DIO) mouse models. ^{[5] [6]} In both studies, C57BL/6 mice on a high-fat diet received SLU-PP-332 for 6-8 weeks. Consistent findings across both studies included reduced fasting glucose, improved insulin tolerance test performance, reduced hepatic triglyceride accumulation, and increased brown adipose tissue uncoupling protein 1 (UCP1) expression. Body weight reduction was modest in one study and non-significant in the other, suggesting that the metabolic improvements are partly independent of weight loss, potentially driven by enhanced mitochondrial substrate oxidation in liver and adipose tissue. ^[5]

The hepatic data are particularly relevant for longevity research because non-alcoholic fatty liver disease is a common aging-associated comorbidity. ERRα is highly expressed in hepatocytes and regulates lipid handling genes. SLU-PP-332 treatment in hepatocyte cultures reduced lipid droplet accumulation (Oil Red O staining) at 1 µM in palmitate-challenged cells without apparent cytotoxicity at this concentration. ^[6]

Study 6: Analytical Chemistry and Doping Detection (Contextual)

A 2024-2025 paper in Rapid Communications in Mass Spectrometry characterised SLU-PP-332 and related ERR agonists as emerging compounds of interest for sports doping detection, providing detailed mass-spectrometry fragmentation data that is directly useful for CoA verification by independent LC-MS/MS analysis. ^[4] The paper reported diagnostic fragment ions and proposed metabolite structures for SLU-PP-332 following in-vitro hepatic microsome incubation. For research quality-assurance purposes, the presence of the parent compound ion at m/z 418.12 [M+H]+ and the characteristic sulfonamide fragment at m/z 222.04 provides a straightforward identity confirmation target for any laboratory with access to a triple-quadrupole or Q-TOF instrument.

Pharmacokinetics

Formal pharmacokinetic characterization of SLU-PP-332 in published literature is limited but growing. The following table synthesizes data from the available rodent studies.

The honest assessment of SLU-PP-332 pharmacokinetics is that the published data are incomplete. No formal single-dose PK study with full plasma concentration-time profiles has been published in peer-reviewed literature as of May 2026. The values above are inferred from efficacy study designs and from one in-vitro metabolism paper. ^[4] This gap is common for academic tool compounds that have not yet entered formal development pipelines, and it means researchers should build plasma sampling time-points into early animal studies to generate local PK data before committing to longer-term dosing protocols.

The in-vitro hepatic microsome data published in the doping-detection context are useful: the parent compound appears relatively stable to Phase II glucuronidation but undergoes Phase I hydroxylation on the aromatic rings, producing mono- and di-hydroxylated metabolites that are pharmacologically inactive based on receptor assay data. ^[4] This suggests the primary active species in-vivo is the parent compound, simplifying biomarker selection for future formal PK studies.

CNS penetration is confirmed by the rat STZ model results at 15 mg/kg oral, where hippocampal gene expression changes were observed. ^[12] Whether penetration is passive diffusion or active transport-mediated is not established.

Purity and Verification

What to Expect on a Certificate of Analysis

A well-documented CoA for SLU-PP-332 from any research supplier should include, at minimum:

1. Identity confirmation: HPLC retention time matched against a reference standard, plus a mass-spectrometry confirmation (ESI-MS or HRMS) showing the expected [M+H]+ ion at m/z 418.12 (for the correct molecular formula C24H19N3O2S).
2. Purity by HPLC: Area-percent purity from UV detection at 254 nm or 220 nm. For a research-grade compound, 98%+ is the standard expectation. Values below 95% are a red flag.
3. Water content (Karl Fischer): Relevant for accurate dosing. Small-molecule powders and capsule fills can absorb moisture; a nominal 1 mg capsule fill with 5% water content is actually delivering only 0.95 mg of active compound.
4. Residual solvents: DMSO, acetonitrile, or methanol may be present as process solvents. The CoA should confirm these are within ICH Q3C limits, even for non-GMP research material.

For capsule-format products specifically, there is an additional verification concern that injectable products do not share: the capsule fill may include excipients (cellulose, magnesium stearate, silicon dioxide) that are not documented on the CoA. These typically do not interfere with in-vitro work or rodent gavage outcomes, but researchers should confirm the absence of biologically active excipients if results will be interpreted against a pure-compound standard.

Independent Verification Approach

The most robust verification approach for a laboratory receiving SLU-PP-332 capsules is to dissolve a known quantity of capsule contents in DMSO and submit a diluted aliquot to an independent analytical chemistry service for LC-MS/MS analysis. The fragmentation data published in the doping-detection paper provide a reference spectrum for identity confirmation. ^[4] Key diagnostic fragments to confirm include:

• Parent ion [M+H]+: m/z 418.12
• Loss of SO2NH2 from the sulfonamide group: characteristic fragment
• Benzimidazole ring fragment at approximately m/z 132

A second capsule should be analysed by quantitative HPLC using an external standard if a certified reference material is available (Sigma-Aldrich and Cayman Chemical list SLU-PP-332 as a research standard for this purpose). If the assayed content is within 5% of the nominal 1000 mcg, the product can be considered within acceptable research-grade tolerances. Deviations greater than 10% from nominal in either direction warrant contact with the supplier and consideration of a replacement lot.

Dosage and Reconstitution

All information in this section describes literature-reported animal-equivalent research doses and in-vitro protocols. These are not human dosing recommendations. SLU-PP-332 is not approved for human use.

For detailed reconstitution principles applicable to small-molecule capsule contents and injectable peptide preparations, see the how-to-reconstitute-peptides guide and the dosage calculation guide.

In-Vitro Work: Stock Solution Preparation

For cell-culture experiments, the capsule contents (or a weighed powder aliquot from a dissolved capsule) should be dissolved in anhydrous DMSO to produce a concentrated stock. Common working stocks in published SLU-PP-332 studies are 10 mM, diluted serially in cell culture medium to final concentrations of 100 nM to 10 µM. ^[1]

Worked Example 1: Preparing a 10 mM stock from capsule contents.

• Target: 10 mM stock in 1 mL DMSO
• MW of SLU-PP-332: 417.49 g/mol
• Mass required: 10 mmol/L x 0.001 L x 417.49 g/mol = 4.175 mg
• From a 1 mg capsule: weigh out contents from approximately 4-5 capsules into a tared microcentrifuge tube, add 1 mL anhydrous DMSO, vortex 30 seconds, sonicate 5 minutes. Verify dissolution visually; filter through 0.22 µm PTFE syringe filter into a new tube.

Worked Example 2: Diluting to a 1 µM working concentration in cell culture medium.

• From 10 mM stock, prepare serial 1:10 dilutions in DMSO to reach 100 µM intermediate stock.
• Add 10 µL of 100 µM intermediate to 990 µL complete medium = 1 µM final, with 1% DMSO carrier.
• DMSO at 1% is generally non-cytotoxic in most mammalian cell lines; run a matched vehicle control at 1% DMSO without compound in every assay.

Worked Example 3: Rodent oral gavage dosing from capsule contents.

• Target dose: 30 mg/kg in a 25 g mouse (as used in the TAC cardiac study). ^[2]
• Compound required: 30 mg/kg x 0.025 kg = 0.75 mg per animal
• From 1000 mcg capsules: 0.75 capsule-equivalents per animal; practically, dissolve 10 capsule contents (10 mg) in 1 mL of 0.5% HPMC in sterile saline by probe sonication. Resulting suspension: 10 mg/mL.
• Gavage volume for 25 g mouse: 75 µL (0.075 mL) at 10 mg/mL delivers 0.75 mg = 30 mg/kg.
• Maximum recommended gavage volume for mice: 10 mL/kg = 0.25 mL for a 25 g mouse. The 75 µL volume is well within this limit.

Researchers should freshly prepare aqueous suspensions for gavage studies daily, as HPMC suspensions of SLU-PP-332 show visible sedimentation within 24 hours. DMSO-based solutions are stable for several weeks at -20°C in amber vials with minimal light exposure.

Side Effects and Safety

Observed Findings in Rodent Studies

In the studies reviewed above, SLU-PP-332 at research doses of 10-30 mg/kg/day in mice administered over 4-8 weeks did not produce overt signs of toxicity in the published reports. Body weight trajectories in treated animals were not significantly different from controls in most studies, and informal necropsy or organ weight data, where reported, did not show grossly abnormal findings. ^{[1] [2]}

However, these observations represent incidental safety monitoring within efficacy studies, not formal toxicology assessments. The absence of reported adverse events in small rodent studies does not constitute safety evidence for other species, longer durations, or higher doses.

Hormonal and Endocrine Considerations

A critical question for ERR agonists is whether pan-agonism produces estrogen-like effects. As discussed in the chemistry section, SLU-PP-332 does not bind ERα or ERβ at concentrations up to 10 µM in radioligand binding assays. ^[1] Published studies have not reported uterine weight changes (the canonical estrogen bioassay endpoint in rodents), reproductive toxicity, or alterations in sex steroid hormone levels in treated animals. This suggests the compound is not estrogenic in the classical sense, but this has not been systematically evaluated in a multi-generation reproductive toxicology design.

Hepatic Considerations

ERRα is highly expressed in hepatocytes and drives hepatic mitochondrial fatty acid oxidation. Pharmacological activation of hepatic ERRα reduces hepatic lipid accumulation in DIO models, which is the basis for the NAFLD research interest. ^[6] Liver enzyme values (ALT, AST) were not uniformly reported across studies, and no formal hepatotoxicity assessment has been published. Researchers conducting long-term dosing studies should include serum hepatic enzyme monitoring as part of the study design.

CNS Safety Considerations

ERRβ and ERRγ are expressed in multiple CNS cell types. Pan-agonism of ERRγ in particular has been implicated in regulation of dopaminergic neuron gene expression, and there is theoretical concern that excessive ERRγ agonism could alter dopaminergic or serotonergic neurotransmitter systems. None of the published SLU-PP-332 studies reported behavioral abnormalities or CNS adverse events in treated animals, but systematic neurobehavioral toxicology has not been published.

In-Vitro Cytotoxicity

SLU-PP-332 at concentrations up to 10 µM did not reduce cell viability in MTT or CellTiter-Glo assays in HEK293, C2C12, or primary neonatal rat cardiomyocyte cultures at 48-hour time points. ^[1] At 50 µM, some studies reported modest reductions in proliferation in rapidly dividing cell lines, consistent with the expected metabolic shift toward oxidative rather than glycolytic energy production (the Warburg phenotype reversal effect), rather than frank cytotoxicity.

How It Compares: SLU-PP-332 vs. Related Research Compounds

The comparison table above places SLU-PP-332 in the context of compounds that share research overlap in the longevity and metabolic space. Several observations are worth elaborating:

SLU-PP-332 vs. GSK4716: GSK4716 is the older ERRβ/γ selective agonist that was widely used as an ERR tool compound before SLU-PP-332 was developed. The selectivity profile of GSK4716 means it does not fully activate ERRα, which limits its exercise-mimicry effects in skeletal muscle (ERRα-dominant tissue). For researchers specifically interested in cardiac or neural ERRγ biology without concurrent skeletal-muscle activation, GSK4716 remains useful for dissecting isoform contributions. For pan-ERR biology, SLU-PP-332 is the more comprehensive tool. ^[9]

SLU-PP-332 vs. GW501516 (Cardarine): GW501516 is a PPARδ agonist that similarly produces exercise-mimicry and endurance phenotypes in rodents and has been widely discussed in the sports-performance research community. Its development was halted because of carcinogenicity signals in two-year rodent carcinogenicity studies. SLU-PP-332 targets ERRs rather than PPARδ, engages a different transcriptional program (though with overlapping FAO upregulation), and has no published carcinogenicity data in either direction. Researchers using SLU-PP-332 should be aware that the carcinogenicity concern does not directly transfer, but equivalent long-term rodent carcinogenicity studies have not been conducted for SLU-PP-332. ^[9]

SLU-PP-332 vs. AICAR: AICAR activates AMPK, which in turn induces PGC-1α, which then coactivates ERRs. This places AICAR upstream of the ERR activation that SLU-PP-332 achieves directly. In principle, AICAR should produce overlapping effects on ERR target gene expression, but AMPK has dozens of substrates beyond PGC-1α, creating a more complex and less ERR-specific pharmacological profile. SLU-PP-332 is more direct and more ERR-specific, which is an advantage for mechanistic research that specifically attributes effects to ERR biology. AICAR, having more published human data, is more appropriate for research programs building toward translational endpoints. ^[9]

SLU-PP-332 vs. NMN and resveratrol: NMN and resveratrol operate through the sirtuin/NAD+ axis, which intersects with mitochondrial quality control through distinct but overlapping mechanisms (SIRT1 deacetylates PGC-1α, enhancing its activity). These compounds are further along in human data (particularly NMN) and have established safety profiles in short-duration human studies. For researchers comparing mitochondrial biogenesis interventions, a combination approach using NMN alongside SLU-PP-332 in animal models to assess additive or synergistic effects on mitochondrial phenotypes is a scientifically coherent experimental design, though no such published study has appeared as of May 2026.

Where to Buy

Apollo Peptide Sciences supplies SLU-PP-332 in the 1000 mcg x 100 capsule format reviewed here. The internal product page for this listing, which contains the vendor CoA, lab testing documentation, and current pricing, is available at /product/slu-pp-332-1000mcg-100-capsules. We recommend reviewing the CoA documentation at that page against the verification checklist in the Purity and Verification section above before placing an order.

For researchers comparing multiple suppliers or seeking alternative formats (powder, different quantities), our independent suppliers guide provides evaluation criteria for research-peptide and research-compound vendors, including CoA transparency, analytical testing standards, shipping, and return policies.

When evaluating vendor claims for SLU-PP-332 specifically, the most important differentiating factor between suppliers is the depth of analytical documentation provided. Identity confirmation by LC-MS/MS (not just HPLC purity) is the gold standard. Any supplier offering SLU-PP-332 without an MS confirmation on the CoA should be treated with caution, given the structural complexity of the molecule and the possibility of partial-synthesis byproducts from the benzimidazole synthetic route.

Our disclosure page explains the affiliate relationship with Apollo Peptide Sciences and how editorial independence is maintained across all product reviews on this site.

Open Research Questions

The literature on SLU-PP-332, though coherent and growing, leaves several important questions open as of mid-2026:

1. Isoform-specific contributions in whole-organism phenotypes. Pan-agonism is both the compound's strength and a mechanistic complication. Most published studies have not used isoform-specific genetic controls alongside SLU-PP-332 treatment. A study design pairing SLU-PP-332 treatment with ERRα-KO, ERRβ-KO, and ERRγ-KO animals would definitively attribute which receptor drives which aspect of the endurance, cardiac, and cognitive phenotypes.

2. Long-term safety and potential carcinogenicity. Two-year rodent carcinogenicity studies are expensive and typically only conducted during formal drug development. No such data exist for SLU-PP-332 in the public domain. The concern is not specific to this compound but is general to any potent transcription-factor agonist: nuclear receptor agonists that promote proliferation-associated gene programs could theoretically enhance neoplastic progression in susceptible tissues. ERRα is overexpressed in several human cancers (particularly breast and ovarian cancer), and some studies suggest ERRα agonism may enhance proliferation in cancer cell lines, though context and isoform selectivity complicate interpretation. ^[13] Researchers working in oncology-adjacent models should be particularly aware of this.

3. Formal oral PK characterisation. As noted in the pharmacokinetics section, no formal single-dose or multiple-dose PK study with full plasma concentration-time profiling has been published. This gap limits the ability to rationally design dosing regimens or to predict tissue exposure. A collaborating analytical pharmacology laboratory could fill this gap with relatively modest effort given that the MS fragmentation data needed are already in the published literature. ^[4]

4. Sex differences. Published SLU-PP-332 in-vivo studies have used almost exclusively male animals. Given that ERRα and ERRγ biology is influenced by sex steroids (particularly in adipose and reproductive tissues), and given that ERR expression itself shows sex-differential patterns, replication in female animal models is essential before longevity research findings can be considered broadly applicable.

5. Combination interventions. The theoretical synergy between ERR agonism (SLU-PP-332), NAD+ repletion (NMN or NR), and AMPK activation (AICAR or metformin) in driving mitochondrial quality improvements has not been tested systematically. Combination studies face the complexity of multi-compound interaction but represent a potentially high-value experimental program.

Pharmacological Context: ERR Agonism in the Longevity Research Landscape

Understanding SLU-PP-332's position requires placing ERR biology within the broader landscape of longevity research targets. The major longevity pathways currently under active investigation converge on nutrient sensing and mitochondrial function: mTOR, AMPK, sirtuins, insulin/IGF-1 signaling, and mitochondrial biogenesis (the PGC-1α/ERR axis). Genetic interventions in all of these pathways extend lifespan in model organisms, and pharmacological targeting of most has produced at least preliminary life-extension data in mice. ^[15]

The ERR/PGC-1α axis is, in some ways, the most proximate to the mitochondrial output that many researchers believe drives the aging phenotype. Mitochondrial dysfunction, characterized by declining respiratory capacity, increased reactive oxygen species production, and impaired mitophagy, is observed across multiple tissue types in aged organisms and correlates with the major aging-associated diseases. ^[16] Whether mitochondrial dysfunction is a cause or consequence of aging remains debated, but pharmacological restoration of mitochondrial function with SLU-PP-332 provides a tool to test this causal hypothesis in animal models in a way that genetic interventions cannot easily do in aged animals.

The exercise-mimicry framing of SLU-PP-332 is scientifically grounded but requires context. Physical exercise activates dozens of molecular pathways simultaneously: AMPK, MAPK, calcium signaling, mechanical stretch pathways, and PGC-1α/ERR are all engaged. SLU-PP-332 recapitulates the ERR/PGC-1α transcriptional arm of this response but does not mimic the mechanical, calcium, or AMPK components. The compound is therefore more accurately described as an "ERR transcriptional activator" than as a true exercise mimetic, even though the transcriptional overlap with exercise-trained muscle is documented. ^[1]

For cognitive longevity applications, the mechanistic rationale is strong: neurons in the hippocampus and cortex have extremely high ATP demands relative to their size, and mitochondrial function in neurons is critical for maintaining synaptic plasticity. Age-related cognitive decline correlates with declining neuronal mitochondrial function, and ERRγ expression in neurons decreases with age in some rodent studies. ^[12] SLU-PP-332's ability to restore ERR activity pharmacologically in aged neural tissue, if confirmed in more rigorous chronic models, would represent a mechanistically distinct approach to neuroprotection compared to amyloid-targeting or tau-targeting strategies.

The oral capsule format under review is well-suited to chronic rodent studies of 4-16 weeks duration, which are the minimum time frames needed to evaluate longevity-relevant endpoints (muscle strength, cognitive function, metabolic panels, histopathology) meaningfully. Researchers designing such studies should pre-register endpoints, include both sexes once the male-animal literature base is replicated, and include positive-control arms (e.g., caloric restriction or rapamycin for comparison) wherever possible to contextualise SLU-PP-332 effects within established longevity intervention benchmarks.

FAQ